reports
Aileron Therapeutics Reports First Quarter 2024 Financial Results and ...
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated Topline results from Cohort 2 evaluating high-dose LTI-03 (5 mg BID) expected in the third quarter of 2024 AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron” or the “Company”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class med...
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
Aileron Therapeutics to Present at Two Upcoming Investor Conferences AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences: Citizens JMP Life Sciences ConferenceDate: Monday, May 13, 2024Time: 12:00 p.m. EDTFormat: Company presentation H.C....
Aileron Therapeutics Announces Closing of Underwritten Registered Dire...
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering AUSTIN, Texas, May 03, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announ...
Aileron Therapeutics Announces Pricing of Underwritten Registered Dire...
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering AUSTIN, Texas, May 01, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonar...
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phas...
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) Low-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a biomarker indicative of epithelial health, suggesting potential therapeutic effect Positive trend was observed in seven of eight IPF biomarkers evaluated Low-dose LTI-03 was well-tolerated, with no safety signal observed Data from Cohort 2 evaluatin...
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financi...
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected to be reported in the third quarter of 2024 Cash runway expected to fund operations and key milestones into the fourth quarter of 2024 AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”, the “Company”, “we”, “our” or “us”) (NASDAQ: ALRN), a biopharmaceutical company advancing a ...
Aileron Therapeutics Announces CEO Transition
Aileron Therapeutics Announces CEO Transition Current President and Chief Operating Officer, Brian Windsor, Ph.D., appointed Chief Executive Officer Dr. Windsor to lead Aileron into a new era focused on advancing a pipeline of first-in-class medicines for orphan pulmonary and fibrosis diseases WALTHAM, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced tha...
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potenti...
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event Topline results from Phase 1b study of LTI-03, Aileron’s novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected in the second quarter of 2024 WALTHAM, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs ...
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, ...
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024 Panel discussion will highlight LTI-03, Aileron’s novel Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it will host a virtual key opinion leader event titled, “Clinical Perspectives on Tre...
Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer C...
Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mutated breast cancer showed that patients in the trial experienced severe neutropenia (Grade 4) and alopecia. The primary endpoint of the Phase 1b open-label trial, which was evaluating ALRN-6924 in patients with breast cancer receiving neoadjuvant or adjuvant tr...
Aileron Therapeutics Regains Compliance with Nasdaq Listing Requiremen...
Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that it received written notice on November 28, 2022 from The Nasdaq Stock Market noting that Aileron has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2), which requires the company to maintain a minimum closing bid price of $1.00 per share, and the matt...
Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split
Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split Common Stock Will Begin Trading on Split-Adjusted Basis on November 11, 2022 BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that it will effect a 1-for-20 reverse stock split of its common stock. The reverse stock split will become effective at 5:00 p.m. ET today. Aileron’s common stock will continue to be traded on the Nasdaq Capital Market under t...
Aileron Therapeutics Reports Third Quarter 2022 Financial Results and ...
Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights Activated multiple existing and new sites under amended Phase 1b breast cancer clinical trial protocol; additional site activations anticipated in 4Q 2022 and 1Q 2023Presented healthy volunteer study results at EORTC-NCI-AACR International Conference demonstrating potential of ALRN-6924 to prevent chemotherapy-induced neutropenia, thrombocytopenia, and anemia, as well as chemotherapy-induced alopeciaPresented new ex vivo data at European Society for Dermatological Research Annual Meeting showing ALRN-6...
Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Vo...
Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference p53-mediated cell cycle arrest results demonstrate potential of ALRN-6924 to prevent chemotherapy-induced neutropenia, thrombocytopenia, and anemia, as well as chemotherapy-induced alopecia (hair loss)Study showed greater degree and longer duration of effect for ALRN-6924 at higher doses, supporting dose selection of 1.2 mg/kg for ongoing ALRN-6924 breast cancer trial3-minute I...
Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data ...
Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022 New ex vivo data demonstrates protection against cyclophosphamide-induced damage to hair follicles and their stem cellsEncore presentation of data presented at Society for Investigative Dermatology in May 2022 shows: ALRN-6924 temporarily arrested the cell cycle in human scalp hair follicles and their stem cellsEx vivo data demonstrated protec...
Aileron Therapeutics to Present and Participate in a Fireside Chat at ...
Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation and participate in a fireside chat at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29, 2022, at 3:30 p.m. ET in ...
Aileron Therapeutics to Present at the H.C. Wainwright 24th Annual Glo...
Aileron Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that a pre-recorded corporate presentation by Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will become available for on-demand viewing at the H.C. Wainwright 24th Annual Global Investment Conference, on Monday, September 12, 2022, at 7:00 a.m. ET. ...
Aileron Therapeutics Reports Second Quarter 2022 Financial Results and...
Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights Company continues to advance ALRN-6924 as a selective chemoprotective agent for all patients with p53-mutated cancer, with immediate focus on breast cancer clinical trialExtended cash runway expected to support operations through end of 1Q 2024Presented new data at the Society for Investigational Dermatology 2022 Annual Meeting suggesting ALRN-6924’s potential to protect against chemotherapy-induced alopeciaReported new data from healthy volunteer study demonstrating ALRN-6924-induced cell cycle arres...
Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phas...
Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer Enhancements to protocol, informed by recent ALRN-6924 data, are designed to improve the opportunity to demonstrate protection against chemotherapy-induced severe neutropenia, alopecia (hair loss) and potentially other toxicities in patients with p53-mutated breast cancerKey protocol enhancements include: Selection of 1.2 mg/kg dose of ALRN-6924 with the goal to extend duration of cell cycle arrest and, thus, chemoprotectionNew primary endpoint t...
Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotect...
Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer Patients on ALRN-6924 were able to stay on treatment longer, completing more of the first 4 cycles of carboplatin/pemetrexed (93% of cycles on ALRN-6924 versus 78% on placebo); this imbalance between treatment arms may have introduced a bias against ALRN-6924 on the composite primary endpoint Evaluating cycles 1-6, the imbalance increases further (79% ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.